Cytochrome P450 activity in rheumatoid arthritis patients during continuous IL-6 receptor antagonist therapy

ConclusionBased on sparse data from three patients, continuous anti-IL-6R therapy seems to cause an acute but transient increase in CYP3A4 activity in rheumatoid arthritis patients, which may be due to a normalization of the inflammation-suppressed CYP activity. Further studies are warranted to understand the mechanism behind this putative transient effect.Trial registration  Registered in the ClinicalTrials.gov database (identifier NCT04842981) on April 13th, 2021.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research